12:00 AM
Oct 10, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Status

JZP-110: Completed Phase III enrollment

Jazz completed enrollment of about 200 patients in the double-blind, placebo-controlled Phase II 14-004 trial evaluating 75, 150 and 300 mg oral JZP-110 once daily for 4 weeks followed by a double-blind, 2-week withdrawal portion. In...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >